Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models
Covered in this story
Call it yourself
No calls on $ACR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Acres Commercial Realty Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.